| Overview |
| bsm-90245r-50µL |
| CD82 Recombinant Antbody Kit (KD-Validated) |
| WB, FCM, IC |
| Knockdown Validated |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthesized peptide derived from human CD82 |
| 200-267/267 |
| Recombinant |
| IgG |
| Lot dependent |
| Affinity Purified |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| -20 °C |
| Target |
| 3732 |
| P27701 |
| CD82; CD82 Molecule 2; TSPAN27; IA4; CD82 Antigen; KAI1; R2; Kangai 1 (Suppression Of Tumorigenicity 6 Prostate; CD82 Antigen (R2 Leukocyte Antigen Antigen Detected By Monoclonal And Antibody IA4)); Metastasis Suppressor Kangai-1; Inducible Membrane Protein R2; Tetraspanin-27; C33 Antigen; Tspan-27; SAR2; Suppressor Of Tumorigenicity 6 Protein; Suppression Of Tumorigenicity 6; R2 Leukocyte Antigen; GR15; 4F9; C33 |
| Cell Line: HT-1080 Knockdown technology: shRNA Knockdown |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IC |
1:1000 |